Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Jyoti D. Patel et al.|New England Journal of Medicine|2020Cited by 835
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M. Gounder, Albiruni Ryan Abdul Razak, Alona Zer et al.|Journal of Clinical Oncology|2016Cited by 165
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Vivek Subbiah, Justin F. Gainor et al.|Nature Reviews Clinical Oncology|2021Cited by 140
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i>-altered cancers.Alexander Drilon, Lori J. Wirth, Vivek Subbiah et al.|Journal of Clinical Oncology|2018Cited by 104
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81